This is a summary of the European public assessment report (EPAR) for Ifirmacombi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ifirmacombi.
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.
Therapeutic Area (MeSH)
N/AATC Code
C09DA04
ATC Item
irbesartan and diuretics
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Ifirmacombi
Medicine Name
Ifirmacombi
Aliases
N/ANo risk management plan link.
